A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

Please provide your email address to receive an email when new articles are posted on . A higher correlation was observed between MRD response and OS among non-transplanted patients vs. transplanted ...

Black race is an independent prognostic factor for lower survival outcomes in AML, regardless of cytogenetics. Black patients with NPM1 mutations had poorer overall survival compared to White patients ...